Le Founder J, Laouirem S, Chapelle M, Albuquerque M, Belghiti J et al (2011) Imaging mass
spectrometry provides fingerprints for distinguishing hepatocellular carcinoma from cirrhosis.
J Proteome Res 10:3755–3765
Lee Y-C, Gajdosik MS, Josic D, Clifton JG, Logothetis C (2014) Secretome analysis of an
osteogenic tumor identifies complex signaling networks mediating cross-talk of cancer and
stromal cells within the tumor microenvironment. Mol Cell Proteomics M114:039909
Licastro F, Caruso C (2010) Predictive diagnosis and personalized medicine for the prevention of
chronic degenerative diseases. Immun Ageing 7(Suppl 1):S1. doi:10.1186/1742-4933-7-S1-S1
Licker V, Turck N, K€ovari E, Burkhardt K, Coˆte M et al (2014) Proteomic analyses of human
substantia nigra identifies novel candidates involved in Parkinson’s disease pathogenesis.
Proteomics 14:784–794
Lincoln T (2007) Danger in the diet. Nature 448:148. doi:10.1038/448148a
Lundberg E, Uhlen M (2010) Creation of an antibody-based subcellular protein atlas. Proteomics
10:3984–3996
MacAleese L, Stauber J, Heeren RMA (2009) Perspectives for imaging mass spectrometry in the
proteomics landscape. Proteomics 9:819–834
Maier SK, Hahne H, Gholami AM, Balluff B, Meding S et al (2013) Comprehensive identification
of proteins from MALDI imaging. Mol Cell Proteomics 12:2901–2910
Mann M, Kulak NA, Nagaraj N, Cox J (2013) The coming age of complete, accurate and ubi-
quitous proteomes. Mol Cell 49:582–590
Mao P, Wang D (2014) Top-down proteomics of a drop of blood for diabetes monitoring.
J Proteome Res 13:1560–1569
Masuda M, Yamada T (2014) Signaling pathway profiling by reversed-phase array for personal-
ized cancer medicine. Biochim Biophys Acta 1854:651–657
Mauvoisin D, Dayton L, Gachom F, Kussmann M (2014) Proteomics and circadian rhytmus: it’s
all about signaling! Proteomics. doi:10.1002/pmic.201400187
McLerran D, Grizzle WE, Feng Z, Bigbee WI, Banez LL et al (2008) Analytical validation of
serum profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem 54:53–60
McQuade LR, Balachandran A, Scott HA, Khaira S, Baker MS, Schmidt U (2014) Proteomics of
Huntington’s disease affected human embryonic stem cells reveals an evolving pathology
involving mitochondrial dysfunction and metabolic disturbances. J Proteome Res 13:
5648–5659
Meng Z, Veenstra TD (2011) Targeted mass spectrometry approach for protein biomarker verifi-
cation. J Proteomics 74:2650–2659
Mitchell P (2010) Proteomics retrenches. Nat Biotechnol 28:665–670
Moon P-G, Lee J-E, You S, Kim T-K, Cho J-H et al (2011) Proteomic analysis of urinary exo-
somes from patients of early IgA nephropathy and thin basement membrane nephropathy.
Proteomics 11:2459–2475
Mueller C, Decarvalho AC, Mikkelsen T, Lehman NL, Calvert V, Espina V (2014) Glioblastoma
cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic
correlations. Cancer Res 74:818–828
Muraoka S, Kume H, Adachi J, Shiromizu T, Masuda T, Ishihama Y, Tomonaga T (2013) In-depth
membrane proteomic study of breast cancer tissue for the generation of a chromosome-based
protein list. J Proteome Res 12:208–213
Nicholson JK (2006) Omics dreams of personalized health care. J Proteome Res 5:2067–2068
Papeta N, Chan KT, Prakash S, Martino J, Kiryluk K, Bellard D et al (2009) Susceptibility loci for
murine HIV-associated nephropathy encode trans-regulations of podocyte gene expression.
J Clin Invest 119:1178–1188
Pastushkova L, Kireev KS, Kononikhin AS, Tiys ES, Popov IA, Starodubtseva NL, Dobrokhotov
IV, Ivanisenko VA, Larina IM, Kolchanov NA, Nikolaev EN (2013) Detection of renal tissue
and urinary tract proteins in the human urine after space flight. PLoS One 8(8), e71652. doi:10.
1371/journal.pone.0071652
The Role of Proteomics in Personalized Medicine 215